我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

阿司匹林在心血管病一级预防的地位

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2016年第2期
页码:
237-240
栏目:
综述
出版日期:
2015-11-25

文章信息/Info

Title:
Aspirin for primary prevention of cardiovascular disease
作者:
孔繁亮; 吴同果
（广州市红十字会医院、暨南大学医学院附属广州红十字会医院心血管医学部，广东 广州 510220）
Author(s):
KONG Fan-liang;  WU Tong-guo
(Department of Cardiology, Guangzhou Red Cross Hospital & Fourth Affiliated Hospital, Jinan University, Guangzhou 510220, Guangdong, China)
关键词:
阿司匹林; 心血管疾病; 一级预防
Keywords:
aspirin;  cardiovascular disease;  primary prevention
分类号:
R971.1
DOI:
-
文献标识码:
A
摘要:
阿司匹林作为急性心肌梗死和冠心病二级预防的基础药物已得到广泛认可，然而近年来关于阿司匹林对心血管疾病的一级预防依然存在争议。阿司匹林可降低心脑血管事件的发生率，但同时又可增加出血事件。如何将其合理地运用在心血管疾病一级预防中使更多的患者获益是临床工作者的一大难题。越来越多的大规模临床研究表明阿司匹林作为心血管疾病一级预防药物的关键在于把握危险分层,进一步评价患者的状况，规范使用阿司匹林将会有效地减少心血管疾病的风险。与此同时国外许多指南及我国专家的共识均能指导医生在心血管疾病一级预防中规范地运用阿司匹林。
Abstract:
The use of aspirin for primary prevention of cardiovascular events in patients at elevated risks for cardiovascular disease (CVD) remains controversial. Some randomized controlled trials have proven the beneficial effect of aspirin in primary prevention. Aspirin prevents deaths, myocardial infarction and ischemic stroke, whereas it increases hemorrhagic stroke and major bleeding. In order to make better use of aspirin in the primary prevention of CVD, we need to estimate the risks of a cardiovascular event in the individual patient. Most guidelines recommend the Framingham risk score that predicts the 10-year risk of developing a cardiovascular event. Recent guidelines present new recommendations for the use of aspirin in the primary prevention. Although aspirin should be used cautiously in the primary prevention of CVD, the beneficial role aspirin plays in the primary prevention of cardiovascular events should be emphasized.

参考文献/References

[1]Hansson L,Zanchetti A,Carruthers SG,et al.Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:principal results of the Hypertension Optimal Treatment(HOT)randomised trial.HOT Study Group[J].Lancet,1998,351(9118):1755-1762.
[2]Ridker PM,Cook NR,Lee IM,et al.A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women[J].N Engl J Med,2005,352(13):1293-1304.
[3]Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group[J].N Engl J Med,1989,321(3):129-135.
[4]Raju NC,Sobieraj-Teague M,Hirsh J,et al.Effect of aspirin on mortality in the primary prevention of cardiovascular disease[J].Am J Med,2011,24(7):621-629.
[5]Rothwell PM,Fowkes FG,Belch JF,et al.Effect of daily aspirin on long-term risk of death due to cancer:analysis of individual patient data from randomised trials[J].Lancet,2011,377(9):31-41.
[6]Berger JS,Lala A,Krantz MJ,et al.Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease:a meta-analysis of randomized trials[J].Am Heart J,2011,162(1):115-124,e2.
[7]Baigent C,Blackwell L,Collins R,et al.Antithrombotic Trialists’(ATT)Collaboration.Aspirin in the primary and secondary prevention of vascular disease:collaborative meta-analysis of individual participant data from randomised trials[J].Lancet,2009,373(9678):1849-1860.
[8]Collins GS,Altman DG.An independent external validation and evaluation of QRISK cardiovascular risk prediction:a prospective open cohort study[J].BMJ,2009,339:b2584.
[9]de Ruijter W,Westendorp RG,Assendelft WJ,et al.Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people:population based observational cohort study[J].BMJ,2009,338:a3083.
[10]Goldstein LB,Bushnell CD,Adams RJ,et al.Guidelines for the primary prevention of stroke:a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J].Stroke,2011,42(2):517-584.
[11]Pignone M,Alberts MJ,Colwell JA,et al.Aspirin for primary prevention of cardiovascular events in people with diabetes[J].J Am Coll Cardiol,2010,55(25):2878-2886.
[12]Mosca L,Benjamin EJ,Berra K,et al.Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update:a guideline from the american heart association[J].Circulation,2011,123(11):1243-1262.
[13]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国心血管病预防指南[J].中华心血管病杂志,2011,39(1):3-22.
[14]Becker RC,Meade TW,Berger PB,et al.The primary and secondary prevention of coronary artery disease:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines(8th Edition)[J].Chest,2008,133(6 Suppl):776S-7814S.
[15]Vandvik PO,Lincoff AM,Gore JM,et al.Primary and secondary prevention of cardiovascular disease:Antithrombotic Therapy and Prevention of Thrombosis,9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J].Chest,2012,141(2 Suppl):e637S-e668S.
[16]US Preventive Services Task Force.Aspirin for the prevention of cardiovascular disease:U.S.Preventive Services Task Force recommendation statement[J].Ann Intern Med, 2009,150(6):396-404.

备注/Memo

备注/Memo:
收稿日期：2014-11-03.
基金项目：广东省科技计划项目资助(2012A030400037)
通讯作者：吴同果，教授，主要从事心血管病研究 Email：wutongguo@sohu.com
作者简介：孔繁亮，硕士生 Email：www.rocket1989@163.com
更新日期/Last Update: 2016-04-25